Cell News and Research

RSS

Study uncovers mechanism for reading extra-long neuronal genes

Neurons in humans and other mammals express many exceptionally long genes, ranging from more than 100 kb to over 2 Mb, that are important for forming synapses and neural circuits.

15 Sep 2026

Aston University partners with Labskin to grow more realistic laboratory-grown human skin

Aston University has joined forces with Yorkshire-based biotechnology company Labskin to develop more realistic laboratory-grown human skin that includes immune cells.

15 Sep 2026

Study uncovers how interferon-alpha treats rare blood cancers

The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators.

15 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

Genetic variant accelerates Huntington’s disease onset by over a decade

A new study has revealed why some people with Huntington disease develop symptoms 10 to 12 years earlier and experience a more aggressive form of the disease.

15 Sep 2026

Optimizing respiratory virus research workflows with VACUBOY

UTS researchers utilize the VACUBOY and VACUSAFE systems to enhance respiratory health studies, streamlining cell culture workflows and improving productivity.

15 Sep 2026

KAIST team uncovers how neurons deliver RNA to distant regions

Much like a courier reading an address on a package, neurons must deliver RNA to the precise locations where it is needed.

15 Sep 2026

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer. (WCLC).

15 Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

15 Sep 2026

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

15 Sep 2026

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure–free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, Republic of Korea.

15 Sep 2026

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC).

15 Sep 2026

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI).

15 Sep 2026

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC).

14 Sep 2026

Cell News and Research

Study uncovers mechanism for reading extra-long neuronal genes

Aston University partners with Labskin to grow more realistic laboratory-grown human skin

Study uncovers how interferon-alpha treats rare blood cancers

Insilico Medicine launches AI initiative to develop longevity vaccines

Genetic variant accelerates Huntington’s disease onset by over a decade

Optimizing respiratory virus research workflows with VACUBOY

KAIST team uncovers how neurons deliver RNA to distant regions

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Improve fermentation and cell culture performance with real-time gas analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®